BACKGROUND: Recent evidence indicates that cancer stem cells play an important role in tumor initiation and maintenance. Additionally, the effect of tissue-resident stem cells located in the surrounding healthy tissue on tumor progression has been demonstrated. While most knowledge has been derived from studies of breast cancer cells, little is known regarding the influence of tissue resident stem cells on the tumor biology of prostate cancer. METHODS: Twenty male athymic Swiss nu/nu mice (age: 6-8 weeks) were randomized into two treatment groups: (1) subcutaneous injection of 10(6) MDA PCa 118b human prostate cancer cells into the upper back or (2) subcutaneous injection of 10(6) MDA PCa 118b cells mixed directly with 10(5) GFP-labeled human adipose tissue-derived stem cells (hASCs). Tumor growth and volumes over the ensuing 3 weeks were assessed using calipers and micro-computed tomography. Immunohistochemistry was performed to identify engrafted hASCs in tumor sections. RESULTS: At 3 weeks after injection, the mean tumor volume in the MDA PCa 118b/hASC co-injection group (1019.95 ± 73.49 mm(3)) was significantly higher than that in the MDA PCa 118b-only group (308.70 ± 21.06 mm(3)). Engrafted hASCs exhibited the nuclear marker of proliferation Ki67 and expressed markers for endothelial differentiation, indicating their engraftment in tumor vessels. CONCLUSION: Our study revealed for the first time that ASCs subcutaneously co-injected with prostate cancer cells engraft and promote tumor progression. Further evaluation of the cross-talk between tumor and local tissue-resident stem cells may lead to new strategies for prostate cancer therapy.
BACKGROUND: Recent evidence indicates that cancer stem cells play an important role in tumor initiation and maintenance. Additionally, the effect of tissue-resident stem cells located in the surrounding healthy tissue on tumor progression has been demonstrated. While most knowledge has been derived from studies of breast cancer cells, little is known regarding the influence of tissue resident stem cells on the tumor biology of prostate cancer. METHODS: Twenty male athymic Swiss nu/nu mice (age: 6-8 weeks) were randomized into two treatment groups: (1) subcutaneous injection of 10(6) MDA PCa 118b humanprostate cancer cells into the upper back or (2) subcutaneous injection of 10(6) MDA PCa 118b cells mixed directly with 10(5) GFP-labeled human adipose tissue-derived stem cells (hASCs). Tumor growth and volumes over the ensuing 3 weeks were assessed using calipers and micro-computed tomography. Immunohistochemistry was performed to identify engrafted hASCs in tumor sections. RESULTS: At 3 weeks after injection, the mean tumor volume in the MDA PCa 118b/hASC co-injection group (1019.95 ± 73.49 mm(3)) was significantly higher than that in the MDA PCa 118b-only group (308.70 ± 21.06 mm(3)). Engrafted hASCs exhibited the nuclear marker of proliferation Ki67 and expressed markers for endothelial differentiation, indicating their engraftment in tumor vessels. CONCLUSION: Our study revealed for the first time that ASCs subcutaneously co-injected with prostate cancer cells engraft and promote tumor progression. Further evaluation of the cross-talk between tumor and local tissue-resident stem cells may lead to new strategies for prostate cancer therapy.
Authors: Jennifer A Tuxhorn; Stephanie J McAlhany; Truong D Dang; Gustavo E Ayala; David R Rowley Journal: Cancer Res Date: 2002-06-01 Impact factor: 12.701
Authors: Daniel Bexell; Salina Gunnarsson; Ariane Tormin; Anna Darabi; David Gisselsson; Laurent Roybon; Stefan Scheding; Johan Bengzon Journal: Mol Ther Date: 2008-11-04 Impact factor: 11.454
Authors: Zhi Gang Li; Paul Mathew; Jun Yang; Michael W Starbuck; Amado J Zurita; Jie Liu; Charles Sikes; Asha S Multani; Eleni Efstathiou; Adriana Lopez; Jing Wang; Tina V Fanning; Victor G Prieto; Vikas Kundra; Elba S Vazquez; Patricia Troncoso; Austin K Raymond; Christopher J Logothetis; Sue-Hwa Lin; Sankar Maity; Nora M Navone Journal: J Clin Invest Date: 2008-08 Impact factor: 14.808
Authors: Emily M Chandler; Bo Ri Seo; Joseph P Califano; Roberto C Andresen Eguiluz; Jason S Lee; Christine J Yoon; David T Tims; James X Wang; Le Cheng; Sunish Mohanan; Mark R Buckley; Itai Cohen; Alexander Yu Nikitin; Rebecca M Williams; Delphine Gourdon; Cynthia A Reinhart-King; Claudia Fischbach Journal: Proc Natl Acad Sci U S A Date: 2012-06-04 Impact factor: 11.205
Authors: Isabele C Iser; Stefanie M Ceschini; Giovana R Onzi; Ana Paula S Bertoni; Guido Lenz; Márcia R Wink Journal: Mol Neurobiol Date: 2015-12-19 Impact factor: 5.590
Authors: Amelie G Ramirez; Dorothy Long Parma; Edgar Muñoz; Kristin D Mendoza; Crystel Harb; Alan E C Holden; Michael Wargovich Journal: Contemp Clin Trials Date: 2017-03-22 Impact factor: 2.226
Authors: Robert M Hughes; Brian W Simons; Hamda Khan; Rebecca Miller; Valentina Kugler; Samantha Torquato; Debebe Theodros; Michael C Haffner; Tamara Lotan; Jessie Huang; Elai Davicioni; Steven S An; Ryan C Riddle; Daniel L J Thorek; Isla P Garraway; Elana J Fertig; John T Isaacs; W Nathaniel Brennen; Ben H Park; Paula J Hurley Journal: Cancer Res Date: 2019-05-23 Impact factor: 12.701